Notably, vafidemstat (ORY-2001), a brain-penetrable LSD1 and monoamine oxidase-B inhibitor, was reported to stop/prevent the development of cognitive impairment in the R6/1 HD mouse model through counteracting transcriptional imbalances caused by REST nuclear translocation in seen in HD (Fig. 7B) (173). This evidence concerns the gene REST and Huntington disease.